S W Fanning
Overview
Explore the profile of S W Fanning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
29
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D, et al.
Res Sq
. 2024 Jul;
PMID: 38978585
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and...
2.
Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D, et al.
bioRxiv
. 2024 Jun;
PMID: 38854123
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and...
3.
Hancock G, Young K, Hosfield D, Joiner C, Sullivan E, Yildiz Y, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):130.
PMID: 36517522
Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit...
4.
Fanning S, Hodges-Gallagher L, Myles D, Sun R, Fowler C, Plant I, et al.
Nat Commun
. 2018 Jun;
9(1):2368.
PMID: 29915250
Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific...